A Phase I trial of CS1003 to assess the drug safety in patients with advanced cancers.

Trial Profile

A Phase I trial of CS1003 to assess the drug safety in patients with advanced cancers.

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs CS-1003 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jan 2018 New trial record
    • 27 Dec 2017 According to a CStone pharmaceuticals media release, a formal application for clinical trial approval has been submitted to Human Research Ethics Committees of the Scientia Clinical Research center in Australia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top